Originally published June 7, 2007 at 12:00 AM | Page modified June 28, 2007 at 4:13 PM
Big shot of cash for Dendreon
In a bid to tread water pending the delayed regulatory approval of its first cancer-fighting drug, Seattle biotechnology company Dendreon...
Seattle Times business reporter
In a bid to tread water pending the delayed regulatory approval of its first cancer-fighting drug, Seattle biotechnology company Dendreon said Wednesday it had raised $75 million from institutional investors.
The company said it may sell $25 million more in convertible debt by early July. The transaction closes Monday.
That "gives us two years worth of cash," Chief Financial Officer Gregory Schiffman told shareholders at the company's annual meeting Wednesday. "We've removed the financial overhang from the company."
The move follows the U.S. Food and Drug Administration's decision to hold off approving Dendreon's prostate-cancer drug therapy, Provenge, originally expected to be marketed this year.
Despite an FDA advisory board recommending approval, the agency requested additional clinical results proving the drug's effectiveness in stopping the spread of prostate cancer and extending patient lives.
That data won't be available until at least next year, forcing Dendreon to put its fast-moving commercialization plans on hold and to cut its work force by 18 percent.
Dendreon's fund-raising effort underscores how small biotech firms struggle to stay afloat even as they jump through the hoops of a strict regulatory examination that can take years.
The process can take its toll not only on shareholders seeking to profit from the $1 billion market in therapies for prostate cancer, but also on patients who pin their hopes for survival on a miracle breakthrough.
Emotions can ride high. Two doctors on the advisory panel who opposed approval of Dendreon's drug received e-mail threats, The New York Times reported earlier in the week.
Provenge belongs to a new class of bio-engineered drugs that spur the immune system to destroy malignant tumors.
Dendreon, like many biotech companies waiting to sell their first scientific breakthroughs, has no income from its products.
At the end of the first quarter, the company had $88.5 million in cash and investments.
![]()
With anticipated capital expenditures of $95 million for 2007, it was on track to end the year with only $25 million, said David Miller, president of Biotech Stock Research, a Seattle-based research firm.
"This just gives them some more wiggling room" until the interim clinical data is available, Miller said.
The choice of selling convertible notes instead of new shares was smart, because selling more stock at the current price would dilute existing shareholders' stake, Miller said.
Dendreon stock has had some wild swings in recent months. Shares skyrocketed when the FDA advisory panel recommended approval in late March, only to tank as the agency withheld its final blessing in May.
Shares rose again when regulators confirmed they would make a decision on interim data from a clinical study that may be available next year.
"It's been an incredibly interesting 2007 for the company," Chief Executive Mitchell Gold told a couple hundred shareholders at the meeting at Dendreon's downtown Seattle offices.
Some investors expressed frustration at the FDA's reluctance to approve Provenge, and the ensuing roller-coaster ride in share prices.
"I was a millionaire one day, and then we got shot down," said Arnie Mass, 71, a retired broker from Chicago who said he helped stage a demonstration in favor of Provenge's approval at a biotech conference there last weekend. "But I still hope."
Angel Gonzalez: 206-515-5644 or agonzalez@seattletimes.com
Copyright © 2007 The Seattle Times Company
NEW - 12:18 AM
Microsoft CFO to exit after tough year of cost-cutting
St. Louis exec now boss of all Boeing giving
Saab's fate uncertain after deal collapses
Reform won't take bite out of health-care profits
Facebook's new share structure hints at public offering

New Beginnings Christian Fellowship
Coming in this Sunday's Pacific Northwest Magazine: Pastor Braxton's mission is to preach a message that appeals to everyone.
general classifieds
Garage & estate salesFurniture & home furnishings
Sporting goods
just listed
Metal Shelving - $35
Moyea SWF To Video Converter Pro - $100
SCHWINN VOYAGEUR GS BRAND NEW - $175
More listings
POST A FREE LISTING
shopping
events for Wednesday, Nov. 25
- Karan Dannenberg Clothier Black Friday Sale
- Black Friday Sale at Julep
- Seattle Lighting November Sale
- Free tours at Theo Chocolate
editors' picks
More shopping guides- Home break-in ends in shootings, Everett police say
- Steve Kelley | Next Seahawks GM should be Mike Holmgren
- Mariners Blog | Jose Lopez appears to be on his way out
- Illegal workers quietly let go
- Amazon, Wal-Mart escalate Web price war
- As glam as he wants to be: Adam Lambert's real debut
- Sprouts, raw fish on attorney's 'do not eat' list
- Bellevue Blog | Bellevue residents blast new bikini espresso stand
- Big demand, grim outlook for state Basic Health Plan
- Husky Men's Basketball Blog | An interview with Enes Kanter's coach
- Bellevue residents blast new bikini espresso stand
254 - Jose Lopez appears to be on his way out
245 - Big demand, grim outlook for state Basic Health Plan
206 - Next Seahawks GM should be Mike Holmgren
155 - Washington State coach Paul Wulff says he's excited about Cougars' future
139 - Hate crimes against gays, religious groups up, FBI says
91 - Man shoots self at Westlake Center
83 - Some fans at Fort Bragg see themselves in Sarah Palin
82 - Teen pimp found guilty of human trafficking
66 - Portland cafe's specialty: medical-marijuana tokes
49
- Sprouts, raw fish on attorney's 'do not eat' list
- Tattoos at Mill Creek church pierce skin, soul
- Food-safety lawyer's wish: Put me out of business
- Illegal workers quietly let go
- Architects, chefs find 'kid' within to build Gingerbread Village
- Nicole Brodeur | Homeless woman bent on giving
- Portland cafe's specialty: medical-marijuana tokes
- Big demand, grim outlook for state Basic Health Plan
- Hutch gets $10M from Bezos family for immunotherapy research
- Rediscovering Moab, 'the most beautiful place on Earth'




